Skip to content
1 min left
0% read
OMFIF logo

OMFIF

Investment Firm
England
Founded 2010

OMFIF functions as an autonomous research institution focused on central banking, economic policy, and public investment.

Share:

OMFIF Overview

OMFIF is a platform offering research analysis and insights on global finance and economic policies. It connects central banks and financial institutions and connects with the government through OMFIF events, discussions, and reports. It aims to foster growth in sectors like digital finance, central banking, and sustainable finance.

Company Details

  • Founder and Chairman: David Marsh
  • Founded: 2010
  • Headquarters: England

Key Features

  • Expert research on the global and financial market.
  • Specializes in topics such as digital currencies, finance, and sovereign debt.
  • Offers global reach by hosting events addressing economic challenges.
  • Operates institutions focusing on digital finance and the Debt Institute.
  • Provides networking opportunities by hosting events, bringing together institutions and policymakers.

Frequently Asked Questions About OMFIF

OMFIF is a finance company. OMFIF functions as an autonomous research institution focused on central banking, economic policy, and public investment.

OMFIF functions as an autonomous research institution focused on central banking, economic policy, & public investment.

OMFIF has been operating since 2010. You can verify their legitimacy through their official website and social media presence.

OMFIF operates in the finance sector of the cryptocurrency industry. Compare OMFIF with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using OMFIF, research their track record (operating since 2010), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. OMFIF is based in England, has been operating since 2010. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

OMFIF is based in England.

OMFIF was founded in 2010.

OMFIF Details

OMFIF Tags

More About OMFIF

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m